Skip to main content
. 2017 Oct 1;2017:6267981. doi: 10.1155/2017/6267981

Figure 2.

Figure 2

PFS rates of target lesions according to the modality of radiotherapy. The IG-IMRT group had a significantly longer median progression-free survival time of target lesions (P = 0.021). The median progression-free survival in the IG-IMRT group and the 3D-CRT group was 15.41 ± 1.51 months and 8.26 ± 1.00 months, respectively. The 1- and 2-year progression-free rates were 68.5% and 20.3% in the IG-IMRT group and 41.4% and 16.9% in the 3D-CRT group, respectively.